Samsung Biologics, Previously Outpaced by Affiliates, Begins Rebound
Surged Over 8% Yesterday, Re-entering the Top 10 by Market Cap
Persistently Weak Amid Strong Performance of Other Samsung Group Stocks
Rebounded After Hitting a 52-Week Low Early This Month
Contract Increases and Foreign Buying Provide Positive Momentum
After a sluggish performance since the beginning of the year and being pushed aside by its Samsung Group affiliates, Samsung Biologics has begun to rebound. The recent series of contract increases has given momentum to the stock recovery, and continued buying by foreign investors has further strengthened this trend.
According to the Korea Exchange on June 25, Samsung Biologics closed the previous day at KRW 1,385,000, up 8.8%. With this surge, Samsung Biologics' market capitalization ranking rose to 9th place (excluding preferred stocks), re-entering the top 10.
At the beginning of the year, Samsung Biologics' share price soared to an all-time high, approaching KRW 2 million. Since then, it has continued to trend downward. Compared to its intraday record high of KRW 1,987,000 on January 15, the stock has dropped by 30.3%. On June 8, it fell as low as KRW 1,228,000 during trading, marking a new 52-week low.
While Samsung Biologics remained in decline, its affiliates, led by Samsung Electronics, outperformed and moved ahead. Samsung Electro-Mechanics, Samsung Life Insurance, and Samsung C&T, which were outside the top 10 in market capitalization at the start of the year, entered the top 10, buoyed by expectations of rising corporate value due to benefits from artificial intelligence (AI) and the appreciation of Samsung Electronics’ stock price. In contrast, Samsung Biologics, which had ranked 4th at the beginning of the year, was pushed out of the top 10.
This was due to the market's focus on semiconductors driven by AI, which left bio stocks neglected, as well as negative effects from the ongoing strike affecting the stock price.
However, after hitting its lowest point, the stock has started to rebound. It has risen by 12.79% from this month's low.
News of contract increases signed this month has served as a catalyst for the rebound. According to the Financial Supervisory Service's electronic disclosure system, Samsung Biologics announced three contract amount changes at the request of its clients this month alone. On June 22, Samsung Biologics disclosed that the value of a contract for pharmaceutical contract manufacturing with a pharmaceutical company in Asia had been changed from KRW 144.6 billion to KRW 215.9 billion. The contract period was also extended from 2028 to 2037.
Previously, on June 17, Samsung Biologics announced that the value of a contract with a U.S.-based pharmaceutical company had been changed from KRW 737.3 billion at the time of signing in April last year to KRW 835.7 billion. On June 9, the company disclosed that the value of a contract with a European pharmaceutical company had increased from KRW 279.6 billion to KRW 400.7 billion.
The steady inflow of foreign investment has also supported the stock’s rebound. Foreign investors have made net purchases of Samsung Biologics shares totaling KRW 167.1 billion so far this month. Except for only two trading days, net buying has been recorded every day this month.
The outlook for the company’s second quarter results this year is also positive. According to financial information provider FnGuide, the consensus for Samsung Biologics’ second quarter performance (average of analysts’ forecasts) is sales of KRW 1.3243 trillion, up 2.7% year-on-year, operating profit of KRW 592.6 billion, up 24.6%, and net profit of KRW 452.5 billion, up 39.5%.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
However, unresolved labor-management conflict remains a risk factor. Last month, the Samsung Biologics labor union launched a full-scale strike, and currently, a form of compliance action is underway, with workers refusing overtime and holiday work. The company is estimated to have incurred approximately KRW 150 billion in losses due to the strike last month. The impact of the strike is considered a variable for second-quarter results. Hong Kahye, a researcher at Daishin Securities, stated, "The strike issue may cause short-term production disruptions and earnings volatility," adding, "Securing new orders will be a key trigger for resolving concerns."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.